Selenium supplementation for people with heart failure
Official title: Selenium Intervention Registry Randomized Trial in Heart Failure
Run by Skane University Hospital · NCT07543562 · Data updated 2026-11-12
This trial will test whether taking a daily selenium supplement helps people with heart failure avoid hospitalization and reduce the risk of death.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4326 (estimated) |
| Sponsor | Skane University Hospital Academic / other |
| Locations | 11 sites (Oslo and 10 other locations) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | March 2030 |
| Study ends | March 2031 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07543562 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with a primary hospital discharge diagnosis of heart failure who are enrolled in the SwedeHF registry and can give informed consent.
✕Probably not a fit
Patients with normal or high selenium levels, non-cardiac causes of symptoms, or severe terminal comorbidities are less likely to benefit from selenium supplementation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
SIRI-HF is a randomized, placebo-controlled, registry-based trial enrolling adults with a primary discharge diagnosis of heart failure recorded in the SwedeHF registry. Participants are randomized to receive daily selenium supplementation or matching placebo in addition to standard medical therapy and are followed for clinical events such as hospitalizations, mortality, and functional outcomes. The pragmatic RRCT design leverages existing registry infrastructure to streamline enrollment and outcome capture across academic hospitals in Sweden and Norway. The trial targets populations in Northern Europe where low selenium status is common to see if correcting deficiency improves cardiac function and clinical endpoints.
Why it matters
Potential benefit: If successful, this could provide a low-cost, widely accessible supplement that reduces hospitalizations and deaths among people with heart failure.
How similar studies have gone: Prior randomized trials have shown mixed results and often included populations with adequate selenium, though observational data and treatment of severe deficiency (e.g., Keshan disease) suggest potential benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: To be considered for inclusion in this study, patients must meet all of the following eligibility requirements: * 18 years of age * primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry * be able to provide documented informed consent by signing and dating the designated consent form. Exclusion Criteria: * Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol
Where it's running
-
Oslo University Hospital
Oslo, Norway Recruiting -
Skånes University Hospital
Malmö, Skåne County, Sweden Recruiting -
Sahlgrenska University Hospital Östra
Gothenburg, Sweden Recruiting -
Sahlgrenska
Gothenburg, Sweden Recruiting -
Ryhov Hospital
Jönköping, Sweden Recruiting -
Linköping University Hospital
Linköping, Sweden Recruiting
Show 5 more locations
-
Skånes University Hospital
Lund, Sweden Recruiting -
Örebro University Hospital
Örebro, Sweden Recruiting -
Karolinska University Hospital
Stockholm, Sweden Recruiting -
Norrlands university Hospital
Umeå, Sweden Recruiting -
Akademiska University hospital
Uppsala, Sweden Recruiting
Study contacts
- Study coordinator: Martin Magnusson, Professor
- Email: siri_hf@ucr.uu.se
- Phone: +46186119515
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How doctors’ reminders about iron treatment may change IV iron use in adults with heart failure
This trial tests whether sending doctors reminders about iron deficiency guidelines helps them use IV iron more often in hospitalized adults with heart failure who are iron deficient.
-
Biomarkers linked to reverse heart healing in people with heart failure and reduced ejection fraction
This study tests blood biomarkers and imaging data to see why some people with HFrEF improve their heart function after standard treatment.
-
Preventing obesity-related HFpEF
We will follow about 250 adults with obesity who are having metabolic bariatric surgery to see if weight loss prevents or reverses early HFpEF.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.